Fish oil shows little effect on Tourette’s tics
Omega-3 fatty acids are found largely in oily fish, like salmon, mackerel and tuna - as well as fish oil pills.
There are biological reasons to believe that omega-3s could help quiet Tourette’s tics, Gabbay said. Lab research suggests, for example, that the fats affect certain brain chemicals involved in nerve-cell communication and inflammation, and also thought to be involved in Tourette’s.
But this is the first clinical trial to pit fish oil against a placebo to test it objectively.
Gabbay and her colleagues randomly assigned 33 children and teenagers with Tourette’s to take either fish oil capsules or placebo capsules that contained olive oil. Depending on their age, the kids on fish oil took 500 or 1,000 milligrams of omega-3 a day.
Tourette Syndrome (TS) is an inherited, neurological disorder characterized by repeated involuntary movements and uncontrollable vocal (phonic) sounds called tics. In a few cases, such tics can include inappropriate words and phrases.
The disorder is named for Dr. Georges Gilles de la Tourette, the pioneering French neurologist who first described an 86-year-old French noblewoman with the condition in 1885.
The symptoms of TS generally appear before the individual is 18 years old. TS can affect people of all ethnic groups; males are affected 3 to 4 times more often than females.
It is estimated that 200,000 Americans have full-blown TS, and that perhaps as many as 1 in 100 show a partial expression of the disorder, such as chronic multiple tics or transient childhood tics.
The natural course of TS varies from individual to individual. Although TS symptoms range from very mild to quite severe, the majority of cases fall in the mild category.
###
Current understanding
TS was originally considered a rare psychogenic condition but is now thought to be a relatively common genetic disorder. It remains misunderstood by the lay public, and many people are still unaware that cursing tics (coprolalia) affect only a minority of patients (8%).
One of the first descriptions of tics appeared in 1825, when the French physician Jean Itard described 10 people with repetitive tics, including complex movements and inappropriate words. Subsequently Charcot assigned his resident, George Gilles de la Tourette, to report on several patients treated at the Salpetriere Hospital for repetitive behaviors. The goal was to define an illness distinct from hysteria and chorea.
In Tourette’s 1885 paper, Study of a Nervous Affliction, he concluded that these patients suffered from a new clinical condition: “convulsive tic disorder.” Tourette and Charcot thought it was untreatable, chronic, progressive, and hereditary. Although Charcot persisted in his efforts to distinguish “Gilles de la Tourette’s tic disease” from other illnesses, his contemporaries generally did not agree.
Over the next century, little progress was made with respect to pathogenesis. A popular theory was that tics resulted from a brain lesion or lesions similar to those seen with rheumatic chorea or encephalitis lethargica. Another commonly proposed idea was that repetitive tics were caused by emotional and psychiatric factors and therefore would be best treated by Freud’s psychoanalytic method.
In the United States, the view that TS was a rare, bizarre psychological disorder prevailed for much of the 20th century. In the 1970s, Drs Arthur and Elaine Shapiro, with Bill and Eleanor Pearl of the fledgling Tourette Syndrome Association (TSA), used the efficacy of haloperidol and other clinical data to support the conclusion that TS was a relatively common neurological disorder and not a mental or emotional problem.
After 20 weeks, the study found, kids in both groups were showing improvements in their tic severity. But the fish-oil group did no better than the placebo group.
However, kids on fish oil were more likely to report improvements in well-being and the impact their tics were having on their lives.
More than half were considered “responders” on that front, versus between one-quarter and one-third of kids in the placebo group.
Exactly what all that means is unclear.
It’s possible, according to Gabbay, that omega-3s affected how kids perceived their tics, even though there was no clear effect on tic severity.
But, she said, “I’m not going to tell parents that omega-3s are the magic pill.”
A larger clinical trial is needed, according to Gabbay. And it would probably be wise to use a different placebo, she noted.
Olive oil is not an ideal placebo, Gabbay explained, because it can indirectly affect the body’s levels of omega-3 fatty acids.
Something like corn oil would be a “better placebo,” she said.
For now, Gabbay recommended that parents pay attention to the amount of omega-3 fatty acids in their children’s diets. If you can get them to eat more fish, that would be a good way to boost their omega-3 intake.
The typical American diet, including that of kids, tends to be low in omega-3 and high in omega-6 fats - which are found in margarine, vegetable oils and an array of snack foods, sweets and fast food. And that imbalance is thought to be generally unhealthy, Gabbay pointed out.
If you can’t get your child with Tourette’s to eat fish, omega-3 capsules might be worth a shot, according to Gabbay. “But don’t have the expectation that it will benefit tic severity,” she said.
A month’s supply of one-gram fish oil capsules can run well over $15.
The supplements seem to be generally safe, Gabbay noted. She and her colleagues found no higher risk of side effects in kids using fish oil compared with the placebo group.
SOURCE: Pediatrics, online May 14, 2012.
###
A Double-Blind, Placebo-Controlled Trial of Omega-3 Fatty Acids in Tourette’s Disorder
RESULTS: At end point, subjects treated with O3FA did not have significantly higher response rates or lower mean scores on the YGTSS-Tic (53% vs 38%; 15.6 ± 1.6 vs 17.1 ± 1.6, P > .1). However, significantly more subjects on O3FA were considered responders on the YGTSS-Global measure (53% vs 31%, P = .05) and YGTSS-Impairment measure (59% vs 25%, P
< .05), and mean YGTSS-Global scores were significantly lower in the O3FA-treated group than in the placebo group (31.7 ± 2.9 vs 40.9 ± 3.0, P = .04). Obsessive-compulsive, anxiety, and depressive symptoms were not significantly affected by O3FA. Longitudinal analysis did not yield group differences on any of the measures.
CONCLUSIONS: O3FA did not reduce tic scores, but it may be beneficial in reduction of tic-related impairment for some children and adolescents with TD. Limitations include the small sample and the possible therapeutic effects of olive oil.
Vilma Gabbay, MD, MS, James S. Babb, PhD, Rachel G. Klein, PhD, Aviva M. Panzer, BS, Yisrael Katz, BS, Carmen M. Alonso, MD, Eva Petkova, PhD, Jing Wang, MS, and Barbara J. Coffey, MD, MS